COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,241 Articles (22,733 medRxiv, 8,508 bioRxiv)

Most recent first Previous |  Page 1258: Articles 12571-12580  | Next

Increased neutralization of SARS-CoV-2 Delta variant by nanobody (Nb22) and the structural basis
Wu, X., Wang, Y., Cheng, L., Zhu, L., Ma, S., Huang, B., Xu, S., Shi, H., Liu, L., Nawaz, W., Ye, S., Wu, Z.
10.1101/2021.09.06.459055 — Posted: 2021-09-07
The vaccinia-based Sementis Copenhagen Vector COVID-19 vaccine induces broad and durable cellular and humoral immune responses
Eldi, P., Cooper, T. H., Prow, N. A., Liu, L., Heinemann, G. K., Zhang, V. J., Trinidad, A. D., Guzman-Genuino, R. M., Wulff, P., Hobbs, L. M., Diener, K. R., Hayball, J. D.
10.1101/2021.09.06.459206 — Posted: 2021-09-07
Durability analysis of the highly effective BNT162b2 vaccine against COVID-19
Puranik, A., Lenehan, P., O'Horo, J. C., Niesen, M. J., Virk, A., Swift, M. D., Kremers, W., Venkatakrishnan, A., Gordon, J. E., Geyer, H. L., Speicher, L. L., Soundararajan, V., Badley, A. D.
10.1101/2021.09.04.21263115 — Posted: 2021-09-07
Both Simulation and Sequencing Data Reveal Multiple SARS-CoV-2 Variants Coinfection in COVID-19 Pandemic
Li, Y., Jiang, Y., Li, Z., Yu, Y., Chen, J., Jia, W., Ng, Y. K., Ye, F., Shen, B., Li, S. C.
10.1101/2021.09.06.459196 — Posted: 2021-09-07
Effectiveness of the mRNA BNT162b2 vaccine six months after vaccination: findings from a large Israeli HMO
Kertes, J., Baruch Gez, S., Saciuk, Y., Supino-Rosin, L., Shamir Stein, N., Mizrahi-Reuveni, M., Ekka Zohar, A.
10.1101/2021.09.01.21262957 — Posted: 2021-09-07
Immune responses in COVID-19 respiratory tract and blood reveal mechanisms of disease severity
Zhang, W., Chua, B., John Selva, K., Kedzierski, L., Ashhurst, T., Heycraft, E., Shoffner, S., Hensen, L., Boyd, D., James, F., Mouhtouris, E., Kwong, J. C., Chua, K., Drewett, G., Copaescu, A., Dobson, J., Rowntree, L., Habe|, J., Allen, L., Koay, H.-F., Neil, J., Gartner, M., Lee, C., Andersson, P., Seemann, T., Sherry, N., Amanat, F., Krammer, F. C., Londrigan, S., Wakim, L., King, N., Godfrey, D., Mackay, L., Thomas, P., Nicholson, S. R., Arnold, K., Chung, A., Holmes, N., Smibert, O., Trubiano, J. A., Gordon, C., Nguyen, T. H., Kedzierska, K.
10.1101/2021.09.01.21262715 — Posted: 2021-09-07
Long-term corticosteroid therapy for patients with severe coronavirus disease 2019 (COVID-19)
Calcaianu, G., Degoul, S., Payen, T., Michau, B., Calcaianu, M., Bresson, D., Debieuvre, D.
10.1101/2021.08.30.21262824 — Posted: 2021-09-07
Immunogenicity of Pfizer mRNA COVID-19 vaccination followed by J&J adenovirus COVID-19 vaccination in two CLL patients
Lyski, Z. L., Kim, S., Xthona Lee, D., Sampson, D., Raue, H. P., Raghunathan, V., Ryan, D., Brunton, A. E., Slifka, M. K., Messer, W. B., Spurgeon, S. E.
10.1101/2021.09.02.21262146 — Posted: 2021-09-07
Infectiousness of places: The impact of human settlement and activity space in the transmission of COVID-19
Liu, L., Wang, H., Zhang, Z., Zhang, W., Zhuang, S., Lv, T., Chio, C.-o., Wang, Y., Dao, R., Tang, C., Ao-Ieong, O.-I.
10.1101/2021.09.02.21263012 — Posted: 2021-09-07
The prevalence of adaptive immunity to COVID-19 and reinfection after recovery, a comprehensive systematic review and meta-analysis of 12 011 447 individuals
Chivese, T., Matizanadzo, J., Musa, O., Hindy, G., Furuya-Kanamori, L., Islam, N., Al-Shebly, R., Shalaby, R., Habibullah, M., Al-Marwani, T., Hourani, R. F., Nawaz, A. D., Haider, M., Emara, M. M., Cyprian, F., Doi, S. A. R.
10.1101/2021.09.03.21263103 — Posted: 2021-09-07

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).